• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

French Development Agency AFD and DNDi sign partnership agreement for control of leishmaniasis in East Africa

Paris, France / Geneva, Switzerland — 8 Oct 2015
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The French Development Agency AFD and the Drugs for Neglected Diseases initiative (DNDi) signed today a partnership agreement EUR for €2 million, spanning to the end of 2018 for the development of a new, safe, and effective oral treatment, to support efforts to control leishmaniasis in East Africa (Sudan, Ethiopia, Kenya and Uganda).
[Français]

Leishmaniasis is the parasitic disease responsible for the largest number of deaths worldwide after malaria. There are several forms of the disease, mainly visceral leishmaniasis (VL or kala-azar), the most deadly with close to 50,000 deaths per year, and cutaneous leishmaniasis (CL), the most common, with 700,000 to 1,300,000 new cases every year. Leishmaniasis affects mostly children (children in East Africa account for over 50% of clinical VL cases).

As with other neglected diseases, there are no fully satisfactory treatments available in terms of safety, efficacy, duration, and cost. DNDi and its partners developed an improved therapy, a combination of sodium stibogluconate a paromomycin (SSG&PM). Although it almost halves the duration of treatment, its administration by intramuscular injections requires a 17-day hospitalization. Therefore, there is, more than ever, a real and urgent need for an oral anti-Leishmania treatment that can be administered close to where the patients live, at village level.

AFD’s funding of the research project will enable DNDi to continue the development of an oral treatment that is safe, effective, easy to administer, and low cost against VL in East Africa. This partnership will fund the clinical study of a new oral treatment combining fexinidazole, currently in clinical development by DNDi for sleeping sickness, and miltefosine.

“For the AFD, the control of neglected diseases is one aspect of health systems strengthening, which is also neglected in many countries”, says Christophe Paquet, Director of the health and social protection division. “The remarkable work achieved by DNDi for over 10 years will provide health systems with more effective, easier to administer, and cheaper drugs to treat diseases which affect mostly the poorest populations. This is why we are proud today to support DNDi’s new project.”

This project will also target post-kala-azar dermal leishmaniasis (PKDL), which affects a large proportion of patients previously treated for VL (50% in certain regions of East Africa). These patients act as a reservoir for VL, and rapid treatment of the most infectious PKDL cases may help reduce the risk of a VL epidemic.

Moreover, targeted training will be administered to strengthen clinical capacities in East Africa.

“Since the inception of our organization, the AFD has supported us consistently, particularly for the development of two non-patented anti-malarial drugs’, comments Dr Bernard Pécoul, Executive Director of DNDi. ‘Recent pandemics highlight the necessity for increased and sustained funding, as well as strong political commitment to support control programmes and R&D on neglected diseases.”

****

About the clinical study on fexinidazole-miltefosine (oral combination treatment against VL)

DNDi will conduct a clinical study of the oral combination treatment of fexinidazole, a new chemical entity (NCE) developed by DNDi for sleeping sickness and which demonstrated some activity against the VL parasite Leishmania donovani, and miltefosine, the first oral drug authorized against VL, but which demonstrated insufficient efficacy as single-drug treatment in children. A combination with another drug may hence increase its efficacy and reduce treatment duration (currently 28 days).

About the Drugs for Neglected Diseases initiative (DNDi)
A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected diseases, in particular leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception in 2003, DNDi has delivered six treatments: two fixed-dose antimalarials (ASAQ and ASMQ) – recently transferred to the Medicines for Malaria Venture; nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness; sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa; a set of combination therapies for visceral leishmaniasis in Asia; and a paediatric dosage form of benznidazole for Chagas disease. DNDi has established regional disease-specific platforms, which bring together partners in disease-endemic countries to strengthen existing clinical research capacity, as well as to build new capacity where necessary. www.dndi.org.

 

About AFD

The French development agency AFD, a public financial institution implementing the policy defined by the French government, works to combat poverty and promote sustainable development.
Present in four continents with a network of 72 offices, AFD funds and supports projects which improve the living conditions of populations, support economic growth and protect the planet.
In 2014, AFD contributed EUR 8.1 billion to support projects in developing countries and in the French overseas territories.
www.afd.fr

 

Media Contact

DNDi
Violaine Dällenbach
vdallenbach@dndi.org
T : +41 22 906 92 47
M : +41 79 424 14 74

AFD
Adrien Absolu
absolua@afd.fr
T : +33 1 53 44 46 96

Cutaneous leishmaniasis Visceral leishmaniasis

Read, watch, share

Loading...
Healthcare worker with patient
Press releases
3 Dec 2023

Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) through KfW grants funding to fast-track access to medicines for poverty-related and neglected diseases

Laboratory staff working
News
3 Dec 2023

DNDi commits to cutting carbon emissions in half by 2030

People entering the Mycetoma Research Centre
Videos
23 Nov 2023

Mycetoma: Neglected but not Forgotten

Nurse caring for patient with a lesion on the feet
Press releases
23 Nov 2023

World’s first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment

People standing under tents at the Run for Neglected Patients
News
23 Nov 2023

DNDi@20 charity run shines the spotlight on neglected diseases in Kenya

Viewpoints
11 Nov 2023

DNDi: 20 years of delivering treatments for neglected patients

MSF Access Campaign Blog
Statements
7 Nov 2023

Seventh meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response

Dr James Orbinski, former President of the MSF International Council, accepting the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières in Oslo, Norway on 10 December 1999
News
30 Oct 2023

MSF uses 1999 Nobel Peace Prize to help found pioneering not-for-profit drug development organization

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License